BCM
CDNA icon

BlueCrest Capital Management’s CareDx CDNA Stock Holding History

BlueCrest Capital Management’s Portfolio CDNA Stock Details CDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-16,487
Closed -$131K – 1516
2018
Q1 		$131K Buy
+16,487
New +$102K ﹤0.01% 1330

Other funds holding CDNA

FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GA
Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return

BlueCrest Capital Management's CDNA Position: Q2 2018 in Review

BlueCrest Capital Management sold out of CareDx (CDNA) in Q2 2018, closing a stake of 16,487 shares — an estimated $131K sold.

BlueCrest Capital Management first reported a position in CDNA in Q1 2018 and held it in 1 quarter. The position peaked at $131K in Q1 2018. 104 funds tracked by Wall St. Rank hold CDNA as of Q2 2018.

  • BlueCrest Capital Management reported no remaining CareDx position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 16,487 CareDx shares in Q2 2018, an estimated $131K.
  • BlueCrest Capital Management first reported a position in CareDx in Q1 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's CareDx position peaked at $131K in Q1 2018.
  • 104 funds tracked by Wall St. Rank held CareDx as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.